The Quantitative Decision-making Special Interest Group (QDM SIG) was formed in October 2017. It is a group of statisticians from industry and academia, with experience and interests in statistical methods for quantitative decision-making in drug development. The objectives of the SIG are:
| Thomas Blondel (Ceva) |
| Nicolas Bonnet (Sanofi) |
| Daniel Bratton (GSK) |
| Sarah Bray (Amgen) |
| Alex Carlton (GSK) (Co-Chair) |
| Jacquie Christie (Sobi) |
| Paul Frewer (AstraZeneca) |
| Heiko Goette (Merck) |
| Tadhg Guerin (Theravance) (Co-Chair) |
| Kimberley Hacquoil (Exploristics) |
| Martin Johnson (UCB Pharma) |
| Kevin Kunzmann (Boehringer Ingelheim) |
| John-Philip Lawo (CSL Behring) |
| Daniel Leibovitz (Incyte) |
| Jesper Madsen (Novo Nordisk) |
| Pavel Mozgunov (Cambridge University) |
| Emmanuel Pham (Nova Discovery) |
| Gustaf Rydevik (UCB Pharma) |
| Gaëlle Saint-Hilary (Saryga) |
| Guido Thömmes (Merck) |
| Katie Thorn (GSK) |
| Stefano Vezzoli (Chiesi Farmaceutici) |
| Stig Johan Wiklund (Captario) |
| Corine Baayen (Lundbeck) |
Lasse Breuning Sluth (Lundbeck) |
Caroline Petit |
Gilles Guillot (CSL Behring) |
For further information, or to join the QDM SIG, please contact our Co-Chairs:
Alex Carlton (GSK) alex.l.carlton@gsk.com
Tadhg Guerin (Theravance) tguerin@theravance.com
This course is aimed at clinical trial statisticians who are new to or with limited experience of machine learning. Attendees will learn about a range of topics in machine learning, including practical sessions in R.
This webinar will explore two different approaches to Correlates of Protection in vaccine development.
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The event will open with an overview on drug development in women’s health from a clinician perspective. This talk is followed by talks about statistical challenges when planning IVF studies and analysing the menstrual cycles.
This webinar will provide an overview of surrogacy for licensing and reimbursement. In turn, the need of extensions of the SPIRIT and CONSORT statement will be defined and outlined, with case studies to support.
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
We will share a brief overview of what Mobilise D is and why it is an important step stone in the development of digital biomarkers, and how Mobilise D outputs can be relevant for you.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
We have exciting new opportunities available for Study Statisticians, Support Statisticians and Exploratory Statisticians at various levels.
